University of Tulsa VC Fund Invests in BioReact AI
Hurricane Ventures, the venture capital fund for The University of Tulsa, has announced an investment in BioReact. BioReact is an AI and analytics platform used for bioprocess development and optimization. The funding is intended to accelerate the company's growth and product development in the biotechnology sector.
- BioReact was founded in 2023 and is headquartered in Indianapolis. The company's co-founders are CEO Mitchell J. Castetter, a former biotech sales executive, and CTO Joanna Lipinski, PhD, who has over 20 years of experience in software and bioinformatics. - The company’s AI-powered platform is designed to unify and analyze data from various bioreactor instruments, using machine learning to model and optimize process variables like media composition, pH, and temperature. It can simulate up to 10,000 in-silico experiments in a single optimization run, aiming to reduce costly and time-consuming physical lab experiments by as much as 40%. - BioReact is the 12th company to receive investment from Hurricane Ventures, which was launched in early 2023 with the goal of raising a $10 million fund to support startups connected to the University of Tulsa. Hurricane Ventures dedicates 25% of its carried interest back to the university to support its Center for Innovation & Entrepreneurship. - Prior to this investment, BioReact had already gained traction with over 600 monthly active users and had processed more than 20 million data points on its platform. The company was also a finalist at Indiana's 2025 Innovation Showcase. - The platform integrates with equipment from major bioreactor manufacturers like Sartorius, Eppendorf, and Infors, automating the alignment of time-series data from both online and offline sources without requiring coding expertise from scientists. - The investment comes as the broader AI-driven bioprocess optimization market is projected to grow from $24.3 billion in 2024 to $39.6 billion by 2029, with such platforms demonstrating the ability to increase yields by up to 20%. - In the wider AI biotech landscape, China has emerged as a major innovation driver, accounting for a significant portion of global AI-driven drug discovery patents and clinical trials. The AI in bioinformatics market in China alone was valued at over $350 million in 2024 and is forecasted to grow at a CAGR of over 51%.
